a year ago
RPRX
AnalystsChris ShibutaniChris Shibutani's Stock Forecasts
AnalystsChris Shibutani
Analyst Ranking
Top 35%
#1719 out of 4998 analysts
Average Return
+1.33%
Win Rate
43%23 out of 53
Risk vs Reward
Poor
Good
Chris Shibutani's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Prometheus Biosciences IncRXDX | +486.79% | $34.07 | $199.92 | 2022-07-19 - 2023-06-15 | Strong Buy |
Mirati Therapeutics IncMRTX | +117.30% | $16.65 | $36.18 | 2017-12-21 - 2018-12-21 | Buy |
Nektar TherapeuticsNKTR | +79.26% | $71.10 | $14.75 | 2022-04-18 - 2023-04-17 | Strong Sell |
Prometheus Biosciences IncRXDX | +75.89% | $113.66 | $199.92 | 2023-01-31 - 2023-06-15 | Strong Buy |
Arena Pharmaceuticals IncARNA | +62.40% | $61.57 | $99.99 | 2021-05-18 - 2022-03-11 | Strong Buy |
Chris Shibutani Analyst Color
Get additional color on Chris Shibutani's coverage of popular stocks
a year ago
AMLX
2 years ago
AMLX
3 years ago
PFE
4 years ago
PFE
4 years ago
JNJ
Chris Shibutani's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vaxcyte IncPCVX | 2 | Strong Buy | $100.00 | +230.58% | Maintains | 5 months ago |
Erasca IncERAS | 7 | Strong Buy | $3.00 | +87.50% | Maintains | 5 months ago |
Seres Therapeutics IncMCRB | 4 | Strong Sell | $15.00 | -22.48% | Maintains | 5 months ago |
Alkermes PLCALKS | 3 | Strong Buy | $32.00 | +10.42% | Maintains | 6 months ago |
Biontech SeBNTX | 6 | Strong Buy | $137.00 | +30.74% | Upgrades | 10 months ago |
Syndax Pharmaceuticals IncSNDX | 3 | Strong Buy | $33.00 | +108.20% | Maintains | 10 months ago |
United Therapeutics CorpUTHR | 4 | Hold | $302.00 | -2.33% | Maintains | 10 months ago |
Royalty Pharma PLCRPRX | 3 | Strong Buy | $51.00 | N/A | Maintains | a year ago |
Johnson & JohnsonJNJ | 2 | Hold | $155.00 | N/A | Maintains | a year ago |
Amylyx Pharmaceuticals IncAMLX | 8 | Hold | $4.00 | N/A | Maintains | a year ago |
Revance Therapeutics IncRVNC | 5 | Hold | $8.00 | N/A | Maintains | a year ago |
Organon & CoOGN | 5 | Hold | $20.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 5 | Hold | $723.00 | N/A | Maintains | a year ago |
Schrodinger IncSDGR | 1 | Hold | $26.00 | N/A | Maintains | a year ago |
Neurocrine Biosciences IncNBIX | 2 | Strong Buy | $153.00 | N/A | Maintains | 2 years ago |
Abbvie IncABBV | 3 | Strong Buy | $173.00 | N/A | Upgrades | 2 years ago |
Bristol Myers Squibb CoBMY | 2 | Strong Buy | $69.00 | N/A | Maintains | 2 years ago |
Eqrx IncEQRX | 3 | Hold | $3.00 | N/A | Maintains | 2 years ago |
Innoviva IncINVA | 2 | Hold | $13.00 | N/A | Maintains | 2 years ago |
Revolution Medicines IncRVMD | 3 | Hold | $23.00 | N/A | Maintains | 2 years ago |
Nektar TherapeuticsNKTR | 3 | Strong Sell | $30.00 | N/A | Maintains | 3 years ago |
Prometheus Biosciences IncRXDX | 2 | Strong Buy | $144.00 | N/A | Maintains | 3 years ago |
Ventyx Biosciences IncVTYX | 1 | Strong Buy | $50.00 | N/A | Initiates Coverage On | 3 years ago |
Kymera Therapeutics IncKYMR | 2 | Strong Buy | $52.00 | N/A | Maintains | 3 years ago |
Pfizer IncPFE | 2 | Strong Buy | $60.00 | N/A | Upgrades | 3 years ago |
Entrada Therapeutics IncTRDA | 3 | Hold | $18.00 | N/A | Maintains | 3 years ago |
Exscientia PLCEXAI | 1 | Strong Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Tango Therapeutics IncTNGX | 1 | Strong Buy | $17.00 | N/A | Initiates Coverage On | 4 years ago |
Arena Pharmaceuticals IncARNA | 1 | Strong Buy | $90.00 | N/A | Initiates Coverage On | 4 years ago |
Repare Therapeutics IncRPTX | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Ardelyx IncARDX | 1 | Buy | N/A | N/A | Initiates Coverage On | 6 years ago |
Puma Biotechnology IncPBYI | 2 | Hold | N/A | N/A | Downgrades | 8 years ago |
Mirati Therapeutics IncMRTX | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 years ago |
Radius Health IncRDUS1 | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Five Prime Therapeutics IncFPRX | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.